Effect of concurrent zidovudine use on the resistance pathway selected by abacavir‐containing regimens

Abstract

The resistance pathway selected upon virological failure of ABC-containing regimens is significantly altered by concurrent ZDV use, but not by concurrent 3TC use. These data may have important implications for the efficacy of subsequent lines of NRTI therapies.